✦ LIBER ✦

Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study)

✍ Scribed by Markku Partinen; Kari Hirvonen; Leni Jama; Anniina Alakuijala; Christer Hublin; Ilkka Tamminen; Juergen Koester; Juergen Reess

Book ID: 116884506
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 117 KB
Volume: 9
Category: Article
ISSN: 1389-9457
DOI: 10.1016/j.sleep.2007.12.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term open-label study of pramipexol

Long-term open-label study of pramipexole in patients with primary restless legs syndrome

✍ Yuichi Inoue; Kenji Kuroda; Koichi Hirata; Naohisa Uchimura; Tatsuo Kagimura; Te 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 234 KB

Efficacy and safety of pramipexole in id

Efficacy and safety of pramipexole in idiopathic restless legs syndrome: A polysomnographic dose-finding study—The PRELUDE study

✍ Markku Partinen; Kari Hirvonen; Leni Jama; Anniina Alakuijala; Christer Hublin; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 261 KB

A 52-week open-label study of the long-t

A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome

✍ Diego Garcia-Borreguero; Ronald Grunstein; Guruswamy Sridhar; Tilman Dreykluft; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 159 KB

Long-term safety and efficacy of rotigot

Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study

✍ Wolfgang Oertel; Claudia Trenkwalder; Heike Beneš; Luigi Ferini-Strambi; Birgit 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 391 KB

Long-term efficacy and safety of gabapen

Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients

✍ Yuichi Inoue; Naohisa Uchimura; Kenji Kuroda; Koichi Hirata; Nobutaka Hattori 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 533 KB

Controlled withdrawal of pramipexole aft

Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome

✍ Claudia Trenkwalder; Karin Stiasny-Kolster; Andreas Kupsch; Wolfgang H. Oertel; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB

## Abstract Although dopamine agonists are becoming first‐line therapy for restless legs syndrome (RLS), few reports describe treatment periods exceeding 12 weeks. Here, 150 RLS patients who had responded to pramipexole during a 6‐month run‐in period (mean dose, 0.50 mg) were randomly assigned to r